Related Experiment Video
Updated: May 30, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study
Maurits E L Arbouw1, Kris L L Movig, Henk-Jan Guchelaar
1Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands.
European Journal of Clinical Pharmacology
|July 23, 2011
Summary
This study found no increased risk of hospitalization for ischemic events in Parkinson's disease patients using dopamine agonists. Research on dopamine agonists and ischemic events in Parkinson's disease (PD) patients showed no significant association.
Area of Science:
- Neurology
- Pharmacology
- Epidemiology
Background:
- Ergoline dopamine agonists have been linked to ischemic complications.
- The general effect of dopamine agonists on ischemic events in Parkinson's disease (PD) patients remains unstudied.
Purpose of the Study:
- To investigate the association between dopamine agonist use and hospitalization for ischemic events in PD patients.
Main Methods:
- A nested case-control study utilized the PHARMO Institute for Drug Outcome Research database.
- Patients aged over 55 receiving levodopa between 1994-2006 were identified.
- Cases hospitalized for ischemic events were matched with controls, assessing dopamine agonist exposure.
Main Results:
- The study included 542 cases and 2,155 controls.
- Dopamine agonist use one year prior to hospitalization showed a 95% probability confidence interval of 0.95-1.49 for ischemic events.
- No significant risk differences were observed between ergoline and nonergoline agonists.
Conclusions:
- The study does not support a link between dopamine agonist use and increased hospitalization risk for ischemic events.
- Findings suggest dopamine agonists may not elevate the risk of hospitalization for ischemic events in Parkinson's disease patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...